Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
Adenocarcinoma
/ drug therapy
Black or African American
/ statistics & numerical data
Age Factors
Aged
Aged, 80 and over
Angiogenesis Inhibitors
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Asian
/ statistics & numerical data
Bevacizumab
/ therapeutic use
Carboplatin
/ administration & dosage
Carcinoma, Endometrioid
/ drug therapy
Carcinoma, Ovarian Epithelial
/ drug therapy
Chemotherapy, Adjuvant
/ methods
Ethnicity
/ statistics & numerical data
Fallopian Tube Neoplasms
/ drug therapy
Female
Hispanic or Latino
/ statistics & numerical data
Humans
Middle Aged
Neoplasm Staging
Neoplasms, Cystic, Mucinous, and Serous
/ drug therapy
Ovarian Neoplasms
/ drug therapy
Paclitaxel
/ administration & dosage
Peritoneal Neoplasms
/ drug therapy
Prognosis
Proportional Hazards Models
Survival Rate
White People
/ statistics & numerical data
African American women
Asian women
Bevacizumab
Elderly
Minority populations
Ovarian cancer
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
03
08
2021
revised:
04
11
2021
accepted:
16
11
2021
pubmed:
4
12
2021
medline:
23
2
2022
entrez:
3
12
2021
Statut:
ppublish
Résumé
Age and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy. Women with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial. All women had surgical staging and received adjuvant chemotherapy with one of three regimens. Cox proportional hazards models were used to evaluate the relationship between OS with age and race/ethnicity among the study participants. One-thousand-eight-hundred-seventy-three women were enrolled in the study. There were 280 minority women and 328 women over the age of 70. Women age 70 and older had a 34% increase risk for death when compared to women under 60 (HR = 1.34; 95% CI 1.16-1.54). Non-Hispanic Black women had a 54% decreased risk of death with the addition of maintenance bevacizumab (HR = 0.46, 95% CI:0.26-0.83). Women of Asian descent had more hematologic grade 3 or greater adverse events and a 27% decrease risk of death when compared to non-Hispanic Whites (HR = 0.73; 95% CI: 0.59-0.90). Non-Hispanic Black women showed a decreased risk of death with the addition of bevacizumab and patients of Asian ancestry had a lower death rate than all other minority groups, but despite these clinically meaningful improvements there was no statistically significant difference in OS among the groups.
Sections du résumé
BACKGROUND
Age and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy.
METHODS
Women with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial. All women had surgical staging and received adjuvant chemotherapy with one of three regimens. Cox proportional hazards models were used to evaluate the relationship between OS with age and race/ethnicity among the study participants.
RESULTS
One-thousand-eight-hundred-seventy-three women were enrolled in the study. There were 280 minority women and 328 women over the age of 70. Women age 70 and older had a 34% increase risk for death when compared to women under 60 (HR = 1.34; 95% CI 1.16-1.54). Non-Hispanic Black women had a 54% decreased risk of death with the addition of maintenance bevacizumab (HR = 0.46, 95% CI:0.26-0.83). Women of Asian descent had more hematologic grade 3 or greater adverse events and a 27% decrease risk of death when compared to non-Hispanic Whites (HR = 0.73; 95% CI: 0.59-0.90).
CONCLUSIONS
Non-Hispanic Black women showed a decreased risk of death with the addition of bevacizumab and patients of Asian ancestry had a lower death rate than all other minority groups, but despite these clinically meaningful improvements there was no statistically significant difference in OS among the groups.
Identifiants
pubmed: 34857397
pii: S0090-8258(21)01607-3
doi: 10.1016/j.ygyno.2021.11.013
pmc: PMC9400113
mid: NIHMS1778548
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Bevacizumab
2S9ZZM9Q9V
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
398-405Subventions
Organisme : NCI NIH HHS
ID : U10 CA180822
Pays : United States
Organisme : NCI NIH HHS
ID : U10 CA180868
Pays : United States
Organisme : NCI NIH HHS
ID : UG1 CA233191
Pays : United States
Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
Gynecol Oncol. 2014 May;133(2):142-6
pubmed: 24517876
Cancer. 2007 Jul 15;110(2):234-43
pubmed: 17559136
Ann Epidemiol. 2015 Aug;25(8):556-63
pubmed: 25986734
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cancer. 1994 Jan 15;73(2):377-83
pubmed: 8293403
Cancer. 2009 Sep 15;115(18):4210-7
pubmed: 19536873
J Natl Cancer Inst. 2013 Jun 5;105(11):823-32
pubmed: 23539755
Gynecol Oncol. 2011 May 1;121(2):364-8
pubmed: 21288564
Epidemiology. 2002 Mar;13(2):231-4
pubmed: 11880767
JAMA Netw Open. 2020 Apr 1;3(4):e202950
pubmed: 32267515
Obstet Gynecol. 2003 Jul;102(1):156-61
pubmed: 12850623
Am J Clin Oncol. 2015 Jun;38(3):278-82
pubmed: 23689643
J Clin Oncol. 2019 Sep 10;37(26):2317-2328
pubmed: 31216226
Cancer. 1993 Jan 15;71(2 Suppl):606-14
pubmed: 8420683
N Engl J Med. 2009 Jul 9;361(2):170-7
pubmed: 19587342
Gynecol Oncol. 2014 May;133(2):353-61
pubmed: 24406291
Gynecol Oncol. 2008 Nov;111(2):161-2
pubmed: 19006712
Gynecol Oncol. 2008 Nov;111(2):166-72
pubmed: 18829086
J Clin Oncol. 2007 Aug 20;25(24):3621-7
pubmed: 17704411
Gynecol Oncol. 2008 Sep;110(3):374-82
pubmed: 18584856
Cancer. 2011 Jul 15;117(14):3242-51
pubmed: 21264829
J Clin Oncol. 2014 Jun 20;32(18):1871-3
pubmed: 24841978
Am J Obstet Gynecol. 2015 Apr;212(4):468.e1-9
pubmed: 25448522
N Engl J Med. 2011 Dec 29;365(26):2473-83
pubmed: 22204724
Adv Med Sci. 2010;55(1):93-8
pubmed: 20513643
J Surg Oncol. 2008 Feb 1;97(2):103-7
pubmed: 17979133
Gynecol Oncol. 2012 Apr;125(1):19-24
pubmed: 22108636
Am J Epidemiol. 2009 Sep 1;170(5):598-606
pubmed: 19605513